45 citations
,
April 2021 in “Current Treatment Options in Oncology” This review discusses cardiovascular risks associated with androgen deprivation therapy in prostate cancer patients and highlights ongoing research, including the potential reduced COVID-19 susceptibility, but reports no new results.
9 citations
,
January 1997 in “Gynecological Endocrinology” This review discusses the regulation of hair growth, causes of excessive androgen secretion, and current safe solutions for hyperandrogenism manifestations in women but reports no new clinical results.
2 citations
,
February 2023 in “F&S Reports” This study found that elagolix treatment did not normalize the ovulatory cycle in patients with polycystic ovarian syndrome.
2 citations
,
October 2015 in “Obstetrics and gynaecology cases - reviews” This case report details a postmenopausal woman with increased libido, hirsutism, and spontaneous orgasms, noting elevated testosterone levels and enlarged ovaries.
January 2019 in “Oncogen” This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.